Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed invasive ovarian epithelial carcinoma or
primary peritoneal carcinoma at time of initial laparotomy No histologically confirmed
noninvasive ovarian malignancy or low malignant potential tumor or carcinomatosis from
other nonovarian or peritoneal sites At least three courses of first-line combination
chemotherapy (platinum and paclitaxel) with either persistent or recurrent disease If no
treatment with first-line paclitaxel, salvage paclitaxel failure must be documented prior
to eligibility Ascites that is cytologically positive for adenocarcinoma or gross evidence
of recurrent disease with ascites, or gross recurrent disease with abdominopelvic washing
cytologically positive for adenocarcinoma Adequate peritoneal distribution by Technetium
99 scan

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Life expectancy:
Greater than 12 weeks Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at
least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5
mg/dL SGOT/SGPT no greater than 2.5 times normal No active hepatitis or chronic liver
failure Renal: Creatinine no greater than 2 mg/dL Other: Not HIV positive No concurrent
immunosuppressive disorders No active systemic infections or active peritonitis
Geographically available for follow-up Not pregnant or nursing

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior viral based gene therapy treatments
or p53 directed vaccines No other prior gene therapy Chemotherapy: See Disease
Characteristics At least 4 weeks since chemotherapy No concurrent chemotherapy Endocrine
therapy: Not specified Radiotherapy: At least 4 weeks since radiotherapy No concurrent
radiotherapy Surgery: At least 4 weeks since surgery, including surgery for a perforated
bowel, bowel anastamosis, colostomy, or ileostomy